Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 35 Rectal Neoplasms 24 Stomach Neoplasms 19 Triple Negative Breast Neoplasms 16 Colorectal Neoplasms 14 Neoplasm Metastasis 12 Adenocarcinoma 9 Pancreatic Neoplasms 8 Esophageal Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 Nasopharyngeal Carcinoma 7 Adenocarcinoma Of Esophagus 7 Neoplasms 6 Colonic Neoplasms 6 Biliary Tract Neoplasms 5 Carcinoma, Non-Small-Cell Lung 4 Esophageal Squamous Cell Carcinoma 3 Squamous Cell Carcinoma of Head and Neck 2 Spinocerebellar Degenerations 2 Pathologic Complete Response 2 Ovarian Neoplasms 2 Neoplasm, Residual 2 Locally Advanced Rectal Cancer 2 Carcinoma 2 Anus Neoplasms 2 Advanced Solid Tumour 2 Somatostatinoma 1 Solid Tumors 1 Resectable Colon Cancer 1 Rectal Cancer Patients 1

Interventions

pertuzumab 5 Trastuzumab 5 Docetaxel 3 tucatinib 2 pyrotinib 1 atezolizumab 1 Paclitaxel 1 Neoadjuvant Therapy 1 Injections 1 Genetic Testing 1 Carboplatin 1 Capecitabine 1 Blood Specimen Collection 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × Capecitabine × 90 days × Clear all

NCT07413939 2026-05-11

BREnnA

Hoffmann-La Roche

Phase 2/3 Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡